Phase II study of iproplatin in metastatic breast carcinoma.
Thirty patients with progressive metastatic breast cancer and one prior chemotherapy regimen were treated with iproplatin at a starting dose of 300 mg/m2 iv every 3 weeks. After the first 11 patients, the starting dose was decreased to 270 mg/m2. There were one complete remission, three partial remissions, and two minor responses. Responses were observed in soft tissue and osseous and visceral areas. Grade 3 nausea and vomiting were observed in 38% of patients, and grade 3 diarrhea occurred in 31%. The dose-limiting toxicity was thrombocytopenia, which required dose de-escalation in 15 patients. No nephrotoxicity, neurotoxicity, or ototoxicity was observed. Iproplatin has modest antitumor activity in this group of previously treated patients with metastatic breast cancer.
Department of Medical Oncology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston 77030.
G N
GN
Hortobagyi
D
D
Frye
F A
FA
Holmes
V
V
Hug
G
G
Fraschini
A U
AU
Buzdar
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000627:therapeutic use* / Q000633:toxicity
D009944:Organoplatinum Compounds; C023359:iproplatin